RiverVest

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Standard Bariatrics, Inc. develops healthcare equipment for weight-loss surgery. The company was incorporated in 2014 and is based in Cincinnati, Ohio.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.

Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Sparrow Pharmaceuticals develops therapies for conditions of corticosteroid excess. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

NexRay is a provider of medical x-ray fluoroscopy systems.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight loss surgeries. The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system to defeat cancer. It offers XTX201, a solution that induces immune activity in tumors and demonstrates improved antitumor activity. The company’s tumor-selective immunotherapies are based on its technology, which maximizes the potency of immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. Xilio Therapeutics, Inc. was formerly known as Akrevia Therapeutics, Inc. and changed its name to Xilio Therapeutics, Inc. in March 2020. The company was incorporated in 2015 and is based in Waltham, Massachusetts.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Kereos, Inc., a biopharmaceutical company, develops a nanoscale drug delivery technology that enables targeted delivery of a range of therapeutic drug compounds, including existing drugs, new drug candidates, and compounds that are too toxic or too fragile to be delivered without the protection and targeting offered by its technology. It offers KER-1001, a cancer therapeutic that incorporates paclitaxel and a cancer therapeutic drug into the targeted nanodroplet; KER-1002, a cancer therapeutic that incorporates a natural product that has been shown to have anti-tumor efficacy in preclinical studies; and KER-1003 that incorporates a natural product that is effective as an anti-angiogenic. The company also provides KER 0001, a diagnostic application platform that detects the presence of angiogenesis. Kereos, Inc. was founded in 1999 and is based in Saint Louis, Missouri.

SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.

Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Lyric Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops therapeutics to improve the care of critically ill and hospitalized patients. The company develops ulimorelin, a macrocyclic agonist of the hormone ghrelin, as LP101 for the treatment of enteral feeding intolerance and for other disorders affecting critically ill patients in the ICU. It develops therapeutics for gastrointestinal indications. The company was founded in 2013 and is headquartered in South San Francisco, California.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Sparrow Pharmaceuticals develops therapies for conditions of corticosteroid excess. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Under the leadership of Jared Tangney and Josh Windmiller, Biolinq is redefining how biomedical innovations can be imagined and commercialized. While conducting his post-doctoral research at the University of California, San Diego in the laboratory for NanoBioElectronics, Josh saw the potential to bring nanotechnology to the medical world. Combining forces with Jared, a PhD in Biomedical Engineering, the two saw the opportunity to bring their minimally-invasive technology to the diabetes space. Finally, people with diabetes will have a better CGM experience that is not only more affordable, but also pain-free.

Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.

Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Centerre Healthcare Corporation develops and operates rehabilitation hospitals. It offers programs for strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and hip/knee/orthopedic problems. The company also provides specialized rehabilitation services for medical, psychological, social, and functional needs of patients and families. Centerre Healthcare Corporation was founded in 2002 and is based in Brentwood, Tennessee.

InterVene, Inc. develops catheter-based therapy to restore valvular competency in patients with chronic venous insufficiency (CVI) in the deep veins. The company was incorporated in 2011 and is based in South San Francisco, California.

IDEV Technologies is an emerging growth medical device company focused on the development of products for endovascular and interventional applications. Currently, IDEV markets SUPERA, a novel self-expanding nitinol stent. Using a patented interwoven design, SUPERA offers improved flexibility, radial strength, and kink and crush resistance compared to other marketed stents. SUPERA is currently approved for use in the treatment of biliary strictures in the US. IDEV is currently enrolling patients in the SUPERB IDE trial to study SUPERA's safety and efficacy when used in the superficial femoral artery (SFA).

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.

Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.

Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight loss surgeries. The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio.

ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Excaliard is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.

InterVene, Inc. develops catheter-based therapy to restore valvular competency in patients with chronic venous insufficiency (CVI) in the deep veins. The company was incorporated in 2011 and is based in South San Francisco, California.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Alleviant Medical, Inc., a medical device company, develops therapies for congestive heart failure. It offers a transcatheter device to treat congestive heart failure. The company's proprietary technology relieves heart failure symptoms, improves the quality of life, and reduces hospital admissions due to heart failure exacerbations. Alleviant Medical, Inc. was founded in 2017 and is headquartered in Austin, Texas.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.

Under the leadership of Jared Tangney and Josh Windmiller, Biolinq is redefining how biomedical innovations can be imagined and commercialized. While conducting his post-doctoral research at the University of California, San Diego in the laboratory for NanoBioElectronics, Josh saw the potential to bring nanotechnology to the medical world. Combining forces with Jared, a PhD in Biomedical Engineering, the two saw the opportunity to bring their minimally-invasive technology to the diabetes space. Finally, people with diabetes will have a better CGM experience that is not only more affordable, but also pain-free.

Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.